This is the authors' abstract. We don't add key points for this paper.
The new oral antiviral drugs for COVID-19 were mainly studied in unvaccinated patients, before the emergence of the Omicron variant. Will they still be of benefit in 2022?
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Coombes et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: